Clinical Significance

This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men aged 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer. 

_{Source: Roche cobas Elecsys free PSA method sheet, V 2.0 2024-09}